Wyeth

Pfizer Corporation

Ono Pharmaceutical Co., Ltd.

Lisa Anne Collins-Racie

Christopher John Corcoran

Bethany Annis Freeman

Edward R LaVallie

Carl Ralph Flannery

Edward Roland Lavallie

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Kimberly Ann Marquette

Xiang-Yang Tan

Riyez Karim

John Adam Nowak

Katy Evangelia Georgiadis

Michael J Agostino

Kathleen N Tomkinson

Stephane Olland

Thomas Saltmarsh Rush, Iii

Tara K Crawford

Stewart Andrews Mackie

Ravindra Kumar

John M McCoy

Kenneth A Jacobs

Phaik-Eng Sum

Gordon G Wong

Vikki A Spaulding

David Merberg

Maurice Treacy

Lidia Mosyak

Hilary Clark

Cheryl Evans

Xiaotian Zhong

Thomas E McDonagh

Lydia Mosyak

Maya Arai

Kim Fechtel

Tracy Hebert

Robert J Steininger, Ii

Lioudmila Gennadievna Tchistiakova

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Antibody to GDF8 and uses thereof

The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.

Polynucleotides encoding recombinant lubricin molecules and uses thereof

Recombinant lubricin molecules and uses thereof

Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura are provided.

The present invention is based on the discovery that &#x3b6;PKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased &#x3b6;PKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of &#x3b6;PKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy.

Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases

This invention relates to aggrecanase polypeptides and aggrecanase polypeptide/ligand complexes, crystals of aggrecanase and aggrecanase polypeptide/ligand complexes, and related methods and software systems.

Aggrecanase structure

Novel polynucleotides and the proteins encoded thereby are disclosed.

Secreted proteins and polynucleotides encoding them

Truncated aggrecanase proteins and nucleotides sequences encoding them as well as processes for producing them are disclosed. Additionally, aggrecanases with amino acid mutations that lead to increased stability and expression levels in comparison with wild-type or native aggrecanases are also disclosed. Aggrecanases of the invention are especially useful for development of compositions for treatment of diseases such as osteoarthritis. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.

Truncated aggrecanase molecules

Growing community of inventors

Acton, MA, United States of America

Lisa Anne Collins-Racie